Latest Breast cancer treatment Stories
Even after chemotherapy dose adjustment Women who are overweight or obese when they are diagnosed with breast cancer are at higher risk of cancer recurrence or related death than are leaner women, according to a new study to be presented to the 8th European Breast Cancer Conference (EBCC-8) today (Friday). This finding held true even though the study mandated that chemotherapy dosage be adjusted for body weight, and adds further to the evidence that lifestyle factors can influence cancer...
Experimenting with cells in culture, researchers at the Johns Hopkins Kimmel Cancer Center have breathed possible new life into two drugs once considered too toxic for human cancer treatment. The drugs, azacitidine (AZA) and decitabine (DAC), are epigenetic-targeted drugs and work to correct cancer-causing alterations that modify DNA. The researchers said the drugs also were found to take aim at a small but dangerous subpopulation of self-renewing cells, sometimes referred to as cancer...
Ivanhoe Newswire) -- Triple-negative breast tumors are lacking all of the known growth receptors that can treat other types of breast cancer, which makes this the most challenging subtype of cancer for health professionals to treat. A new study suggests that by putting a stop to an abundant growth-promoting protein will cause breast tumors to regress. Patients with triple-negative breast tumors usually tend to relapse earlier and have shorter survival rates. Patients with this type of...
Scientists have uncovered a marker of DNA damage that could predict who will respond to platinum-based chemotherapy drugs like cisplatin or carboplatin. These drugs are widely used for ovarian cancer, but as with most cancer drugs, it can be difficult to predict who will respond to therapy. A team of researchers from the Dana-Farber Cancer Institute found that this marker, telomeric allelic imbalance or tAI, could predict sensitivity to therapy in patients with triple-negative breast...
Testing a breast cancer tumor for its genomic signature can help identify which patients will need adjuvant systemic therapy (additional chemotherapy) after surgery, and spare its use in those for whom it is not necessary, according to the results of a study to be presented to the 8th European Breast Cancer Conference (EBCC-8) today (Thursday). Dr. Sabine Linn, an Associate Professor of Medical Oncology at The Netherlands Cancer Institute, Amsterdam, The Netherlands, will say that this is the...
IRVINE, Calif. and AMSTERDAM, March 22, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company, today announced that five-year follow-up data from the RASTER observational study indicates that its MammaPrint prognostic assay for breast cancer can help reduce adjuvant chemotherapy by 20 percent in patients deemed 'Low Risk.' From 2004 to 2006, the MircoarRAy PrognoSTics in Breast CancER study, known as RASTER, enrolled 427 women with primary breast...
Detecting the presence of circulating tumor cells (CTCs) in the blood of women with early breast cancer after surgery but before the start of chemotherapy can provide useful information about their chances of surviving the disease. CTCs are cancer cells which are detectable in patients with a solid tumor and their value in the prognosis of metastatic breast cancer has been known for a few years. Until now, however, there has been little information about their role in early disease....
VIENNA, March 22, 2012 /PRNewswire/ -- Dune Medical Devices, the manufacturer of the MarginProbe(®) System, held a satellite symposium featuring discussions with experts in the field of breast cancer regarding the treatment of women with early stage breast cancer and the importance of margin assessment in breast conserving surgery. The panel conducted a thorough review of clinical experience with the MarginProbe System, designed to improve a surgeon's ability to identify the...
University of Miami study and breast cancer's course A team of researchers led by Michael H. Antoni, director of the Center for Psycho-Oncology Research at the University of Miami (UM) has shown that a stress management program tailored to women with breast cancer can alter tumor-promoting processes at the molecular level. The new study recently published in the journal Biological Psychiatry is one of the first to link psychological intervention with genetic expression in cancer patients....
GENEVA, March 21, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of three new Oncotype DX® studies including data demonstrating the test's cost-effectiveness within the German and Hungarian healthcare systems, and Israeli data showing the test's impact on treatment decisions in early-stage invasive breast cancer patients with lymph-node positive status. These findings will be presented during poster sessions at the 8th European Breast Cancer...
